<DOC>
	<DOCNO>NCT01126892</DOCNO>
	<brief_summary>A multicenter , open label study Nilotinib CML patient PH + imatininb resistant blast crisis , accelerate phase chronic phase . The main purpose evaluate safety efficacy Nilotinib .</brief_summary>
	<brief_title>A Study Nilotinib Adult Patients With Imatinib Resistant - Intolerant Chronic Myeloid Leukemia Blast Crisis , Accelerated Phase Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Stratum 1 : 1 . Currently participate Novartis study CAMN107A2109 2 . Written sign date informed consent prior study procedure perform Stratum 2 : 1 . Male female 2 . &gt; 18 year 3 . ECOG 0,1,2 4 . ASL/ALT &lt; = 2.5 ULN &lt; = 5.0 ULN 5 . Alcaline Phosfatase &lt; = 2.5 ULN 6 . Serum Bilirrubin &lt; = 1.5 ULN 7 . Serum Creatinine &lt; = 1.5 ULN creatinine clearance &gt; =50 ml/min / 24 hour 8 . Serum Lipase &lt; = 1.5 ULN Stratum 1 stratum 2 : 1 . Reduction cardiac function 2 . Use Coumadin 3 . Other severe medical concurrent condition 4 . Treatment medication prolong QT interval . 5 . Mayor surgery 15 day inclusion protocol 6 . Pregnant woman lactation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Disease ,</keyword>
	<keyword>Resistance ,</keyword>
	<keyword>Intolerance</keyword>
</DOC>